Navigation Links
COPD Tops Asthma as the Focus Indication for Next Generation Respiratory Therapies at the 2012 American Thoracic Society Conference
Date:5/31/2012

NEW YORK, May 31, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials, updates, and intelligence recently reviewed the results presented at the American Thoracic Society (ATS) conference held May 18-23, 2012 in San Francisco, CA. The strong competition to launch the next fixed dose combination (FDC) blockbuster for chronic obstructive pulmonary disease (COPD) was of particular interest to reviewer Jennifer Stacey, Citeline's Analyst in Autoimmune/Inflammation.

(Photo: http://photos.prnewswire.com/prnh/20120531/NE16127-INFO )

In the absence of results from GlaxoSmithKline and Theravance's market-leading RELOVAIR program, top COPD trials data presented at the conference include results from Novartis' Phase III NVA237 GLOW2 trial and final Phase II data from Boehringer Ingelheim's olodaterol monotherapy program. Both drugs provided significant improvement in bronchodilation with once-daily dosing, and these studies supported the dose selections for their respective FDC trials. Mid-sized companies Almirall and Forest showed sustained success of their partnered aclidinium bromide drug program, while privately-held Pearl Therapeutics divulged eight clinical publications at ATS, revealing statistically significant efficacy results and future plans for their LAMA/LABA (glycopyrrolate+formoterol fumarate), PT003.

"The presentations at ATS this year provide further evidence of high competition to launch next generation FDC respiratory drugs. COPD has superseded asthma as the lead indication in the market race, most likely due to the FDA's new safety controls pertaining to limited use of all LABA-containing drugs in asthma as well as the unmet need for improved therapies for COPD," states Ms. Stacey, "Additionally, it appears that most companies are strategically conducting trials to launch their novel LAMA or LABA as monotherap
'/>"/>

SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
3. Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Inverseon Announces Positive Phase IIa Asthma Study
8. Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma
9. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... N.J., July 30, 2015 PTC Therapeutics, Inc. ... and reported financial results for the second quarter ending ... on many fronts across the organization.  We are excited ... muscular dystrophy clinical trial ever conducted with topline results ... Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is ...
(Date:7/30/2015)... 30, 2015  Growth of the U.S. nonprescription market ... former prescription users to the OTC market. Due to ... robust Rx-to-OTC switch activity over the next five years ... many new brands entering the market into existing categories. ... five years (even those with low to moderate likelihood), ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Oct. 27 Pharmos Corporation (Pink Sheets: PARS ... nine-month period ended September 30, 2010. These results are included ... been filed with the SEC. During the quarter ... potential partners for Dextofisopam, its drug for irritable bowel syndrome ...
... N.J., Oct. 27 Systech International, innovator of ... Pac Automation, a leading supplier of end-of-line packaging ... integrated solution for global serialization requirements at Pack ... attendees have the opportunity to examine first hand ...
Cached Medicine Technology:Pharmos Corporation Reports 2010 Third Quarter Results 2Pharmos Corporation Reports 2010 Third Quarter Results 3Pharmos Corporation Reports 2010 Third Quarter Results 4Systech and Pester Pac Automation Exhibit Integrated Serialization Solution at Pack Expo 2010 2
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned ... debuted their new type of sod called Leisure Time(TM) zoysia . It's nicknamed ... , To commemorate introduction of this new type of sod, Super-Sod is giving away ...
(Date:7/31/2015)... ... , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and ... of Exilis non-surgical fat reduction in New York. Due to its unparalleled level ... clientele. Many patients travel to New York to get their non-surgical skin tightening ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Sculpted ... , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in ... in January 2014 for treating the outer thighs. The original applicator required a ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... Coco ... the athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, ... coconut water that can claim “no added sugar” on the market, is a natural ...
(Date:7/31/2015)... , ... July 31, 2015 , ... According to an ... experts gathered to see if they could reach a consensus on the steps that ... and facelifts. Overall, the group reached 90 percent consensus on a series of steps ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... than doubled since the collapse of the Soviet Union, according ... women smoked, compared to almost 15 per cent by 2003. ... has risen from 57 per cent to 63 per cent. ... Tobacco Control, blame the privatisation of the previously state owned ...
... Research Institute (CRI) announced today that it has brought ... Sabin Vaccine Institute, and the Cancer Vaccine Collaborative, a ... Ludwig Institute for Cancer Research (LICR), to form the ... a unified voice in the cancer vaccine field and ...
... annual,Guaranteed Living Benefits (GLB) survey of leading U.S. variable ... offered,include some form of GLB., Total sales of ... 87% of total VA sales, stable relative to 2004 ... up to 95% during the first,half of 2007, demonstrating ...
... MEDai, Inc., headquartered in,Orlando, FL, a ... its longstanding Pinpoint Quality(TM) client, Sharp,HealthCare of ... Malcolm Baldrige National,Quality Award., The Baldrige ... for quality and organizational performance excellence. Congress,established ...
... Walsh appears in PSAs for personal health record ... American Health Information,Management Association (AHIMA) launched the "It,s ... healthcare consumers on the,importance of improving the management ... (PHR)., This campaign encourages Americans -- especially ...
... In a reversal of what has,become the norm, Link ... coupled with two hours of live phone,tech support and ... EZM Web tracks and controls maintenance for any ... control via the Web. It is accessible,from anywhere in ...
Cached Medicine News:Health News:Number of Russian women smokers has doubled since Soviet collapse 2Health News:Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 2Health News:Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 3Health News:Milliman Survey Confirms Continued Dominance of Guarantees in Variable Annuity Retirement Income Products 2Health News:Milliman Survey Confirms Continued Dominance of Guarantees in Variable Annuity Retirement Income Products 3Health News:MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award 2Health News:MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award 3Health News:AHIMA Launches National PHR Consumer Awareness Campaign 2Health News:Maintenance Software Company Bucks Trend, Offers Unlimited No-Charge Product Tech Support 2
... display of corneal layers: endothelium, ... epithelial layers. Accurate analysis of ... keratocytes, nerve fibres, basal & ... surgery and pathology: optical pachymetry, ...
Ahmed Glaucoma Valve (small size)....
... Long-term biocompatibility is established. Provides a robust ... ensure correct positioning on the globe. Pressure ... which, when covered by Tenons tissue, acts ... postoperative hypotony. The range of implants allows ...
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
Medicine Products: